{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:13:24Z","timestamp":1790162004476,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04350-4","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:10:58Z","timestamp":1775844658000},"page":"4376-4388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5693-9786","authenticated-orcid":false,"given":"Patricia","family":"Willisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8892-9479","authenticated-orcid":false,"given":"Beatriz","family":"V\u00e1zquez-Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-7107","authenticated-orcid":false,"given":"Ana","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3056","authenticated-orcid":false,"given":"Irene Cienfuegos","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4359-5318","authenticated-orcid":false,"given":"Roc\u00edo","family":"del Castillo-Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1784-7203","authenticated-orcid":false,"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6893-6284","authenticated-orcid":false,"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-8174","authenticated-orcid":false,"given":"Jos\u00e9 Daniel Subiela","family":"Henr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-0234","authenticated-orcid":false,"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-0507","authenticated-orcid":false,"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"4350_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"key":"4350_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/JAMA.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u201346. https:\/\/doi.org\/10.1001\/JAMA.2025.0228.","journal-title":"JAMA"},{"key":"4350_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/CAAC.70011","volume":"75","author":"NS Wagle","year":"2025","unstructured":"Wagle NS, Nogueira L, Devasia TP, Mariotto AB, Yabroff KR, Islami F, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin. 2025;75:308\u201340. https:\/\/doi.org\/10.3322\/CAAC.70011.","journal-title":"CA Cancer J Clin"},{"key":"4350_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/S41391-019-0157-Y","volume":"23","author":"SA Fletcher","year":"2020","unstructured":"Fletcher SA, von Landenberg N, Cole AP, Gild P, Choueiri TK, Lipsitz SR, et al. Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020;23:81\u20137. https:\/\/doi.org\/10.1038\/S41391-019-0157-Y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4350_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9122653","author":"G Aurilio","year":"2020","unstructured":"Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020. https:\/\/doi.org\/10.3390\/CELLS9122653.","journal-title":"Cells"},{"key":"4350_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/ANNUREV-MED-051418-060357","volume":"71","author":"RJ Auchus","year":"2020","unstructured":"Auchus RJ, Sharifi N. Sex Hormones and Prostate Cancer. Annu Rev Med Annu Rev Med. 2020;71:33\u201345. https:\/\/doi.org\/10.1146\/ANNUREV-MED-051418-060357.","journal-title":"Annu Rev Med Annu Rev Med"},{"key":"4350_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/JU.0000000000002759","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions. J Urol. 2022;208:26\u201333. https:\/\/doi.org\/10.1097\/JU.0000000000002759. (Wolters KluwerPhiladelphia, PA).","journal-title":"J Urol"},{"key":"4350_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/RRU.S303215","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol Res Rep Urol. 2022;14:87\u2013108. https:\/\/doi.org\/10.2147\/RRU.S303215.","journal-title":"Res Rep Urol Res Rep Urol"},{"key":"4350_CR9","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol J Clin Oncol. 2019;37:2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol J Clin Oncol"},{"key":"4350_CR10","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN study. J Clin Oncol. 2021;39:2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"key":"4350_CR11","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the Phase III ARASENS trial. J Clin Oncol J Clin Oncol. 2023;41:3595\u2013607. https:\/\/doi.org\/10.1200\/JCO.23.00041.","journal-title":"J Clin Oncol J Clin Oncol"},{"key":"4350_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.115806","author":"QD Xia","year":"2023","unstructured":"Xia QD, Zhang SH, Zeng N, Lu YC, Qin BL, Wang SG. Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: current application and future perspectives. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.115806.","journal-title":"Biomed Pharmacother"},{"key":"4350_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.UROLONC.2025.08.017","author":"BA Maiorano","year":"2026","unstructured":"Maiorano BA, Mercinelli C, Cigliola A, Tateo V, Gandaglia G, Briganti A, et al. Addition of androgen-receptor pathway inhibitors to standard of care in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Urol Oncol. 2026. https:\/\/doi.org\/10.1016\/J.UROLONC.2025.08.017.","journal-title":"Urol Oncol"},{"key":"4350_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_SUPPL.145","author":"J Parrish","year":"2024","unstructured":"Parrish J, Polascik TJ, Hong A, El-Chaar NN, De Hoedt AM, Kim J, et al. Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) \u2013doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_SUPPL.145.","journal-title":"J Clin Oncol"},{"key":"4350_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/S41391-025-01000-8","author":"SJ Freedland","year":"2025","unstructured":"Freedland SJ, Hong A, El-Chaar N, De Hoedt AM, Kim J, Evans C, et al. Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2025. https:\/\/doi.org\/10.1038\/S41391-025-01000-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4350_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26167667","volume":"26","author":"M Lopez-Valcarcel","year":"2025","unstructured":"Lopez-Valcarcel M, Lopez-Campos F, Zafra-Mart\u00edn J, Cienfuegos Belmonte I, Subiela JD, Ruiz-Vico M, et al. Biomarkers in localized prostate cancer: from diagnosis to treatment. Int J Mol Sci. 2025;26:167667. https:\/\/doi.org\/10.3390\/IJMS26167667.","journal-title":"Int J Mol Sci"},{"key":"4350_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1148\/RADIOL.2019181931","volume":"292","author":"R Perez-Lopez","year":"2019","unstructured":"Perez-Lopez R, Tunariu N, Padhani AR, Oyen WJG, Fanti S, Vargas HA, et al. Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art. Radiology. 2019;292:273\u201386. https:\/\/doi.org\/10.1148\/RADIOL.2019181931.","journal-title":"Radiology"},{"key":"4350_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/S41391-022-00544-3","volume":"26","author":"A Pozdnyakov","year":"2023","unstructured":"Pozdnyakov A, Kulanthaivelu R, Bauman G, Ortega C, Veit-Haibach P, Metser U. The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:240\u20138. https:\/\/doi.org\/10.1038\/S41391-022-00544-3.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4350_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2214\/AJR.20.23912","volume":"216","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic accuracy of 68Ga-PSMA PET\/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2021;216:599\u2013607. https:\/\/doi.org\/10.2214\/AJR.20.23912.","journal-title":"AJR Am J Roentgenol"},{"key":"4350_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/J.EURURO.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/J.EURURO.2024.03.027.","journal-title":"Eur Urol"},{"key":"4350_CR21","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.125.270710","volume":"67","author":"KM Buch-Olsen","year":"2026","unstructured":"Buch-Olsen KM, Vilstrup MH, Hansen S, Poulsen MH, Holdgaard PC, Zieger KEA, et al. Primary staging of intermediate- and high-risk prostate cancer using [18F]PSMA-1007 PET\/CT and [18F]NaF PET\/CT: a head-to-head comparison of diagnostic accuracy, staging, and patient management. J Nucl Med. 2026;67:jnumed.125.270710. https:\/\/doi.org\/10.2967\/JNUMED.125.270710.","journal-title":"J Nucl Med"},{"key":"4350_CR22","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.125.270537","volume":"67","author":"JJ Cerci","year":"2026","unstructured":"Cerci JJ, Fanti S, Lobato EE, Kumar R, Kunikowska J, Al-Ibraheem A, et al. 68Ga-PSMA-11 in staging of unfavorable intermediate- and high-risk prostate cancer reduces indication for noncurative prostatectomy: a prospective, multicenter, IAEA study. J Nucl Med. 2026;67:jnumed.125.270537. https:\/\/doi.org\/10.2967\/JNUMED.125.270537.","journal-title":"J Nucl Med"},{"key":"4350_CR23","doi-asserted-by":"publisher","DOI":"10.2967\/JNUMED.125.270822","volume":"66","author":"C Madsen","year":"2025","unstructured":"Madsen C, Zacho HD, Fugl\u00f8 D, Nielsen K, Kongsted P, Bisbjerg R, et al. 18F-PSMA PET\/CT versus 18F-NaF PET\/CT for staging and treating newly diagnosed high-risk prostate cancer: a prospective single-center study. J Nucl Med. 2025;66:jnumed.125.270822. https:\/\/doi.org\/10.2967\/JNUMED.125.270822.","journal-title":"J Nucl Med"},{"key":"4350_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Zhou Q, Hankey W, Fang X, Yuan F. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13:7. https:\/\/doi.org\/10.1038\/s41419-022-05084-1. (Nature Publishing Group; 2022;13:632-.).","journal-title":"Cell Death Dis"},{"key":"4350_CR25","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1158\/1078-0432.CCR-12-0931","volume":"19","author":"R Ferraldeschi","year":"2013","unstructured":"Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res Clin Cancer Res. 2013;19:3353\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0931.","journal-title":"Clin Cancer Res Clin Cancer Res"},{"key":"4350_CR26","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/13543784.2018.1484107","volume":"27","author":"AE Dellis","year":"2018","unstructured":"Dellis AE, Papatsoris AG. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. Expert Opin Investig Drugs. 2018;27:553\u20139. https:\/\/doi.org\/10.1080\/13543784.2018.1484107.","journal-title":"Expert Opin Investig Drugs"},{"key":"4350_CR27","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-12-2910","volume":"19","author":"J Hoffman-Censits","year":"2013","unstructured":"Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res Clin Cancer Res. 2013;19:1335\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2910.","journal-title":"Clin Cancer Res Clin Cancer Res"},{"key":"4350_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/S40262-023-01268-W","volume":"62","author":"E Podgor\u0161ek","year":"2023","unstructured":"Podgor\u0161ek E, Mehra N, van Oort IM, Somford DM, Boerrigter E, van Erp NP. Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide. Clin Pharmacokinet Clin Pharmacokinet. 2023;62:1049\u201361. https:\/\/doi.org\/10.1007\/S40262-023-01268-W.","journal-title":"Clin Pharmacokinet Clin Pharmacokinet"},{"key":"4350_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178604","volume":"134","author":"X Zhu","year":"2024","unstructured":"Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, et al. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J Clin Invest. 2024;134:178604. https:\/\/doi.org\/10.1172\/JCI178604.","journal-title":"J Clin Invest"},{"key":"4350_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.891886","author":"PC Lara","year":"2022","unstructured":"Lara PC, Rodr\u00edguez-Melc\u00f3n JI, Palacios-Eito A, Lozano A, Herv\u00e1s-Mor\u00f3n A, Villafranca E, et al. Phase II study of ENZAlutamide combined with hypofractionated radiation therapy (ENZART) for localized intermediate risk prostate cancer. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/FONC.2022.891886.","journal-title":"Front Oncol"},{"key":"4350_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet Lancet. 2022;399:447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet Lancet"},{"key":"4350_CR32","doi-asserted-by":"publisher","first-page":"S1743","DOI":"10.1016\/j.annonc.2025.09.102","volume":"36","author":"PL Nguyen","year":"2025","unstructured":"Nguyen PL, Sweeney C, Stockler MR, Thomas H, Mak B, Zhang A, et al. LBA86 randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303). Ann Oncol. 2025;36:S1743\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.102.","journal-title":"Ann Oncol"},{"key":"4350_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17010099","author":"J G\u00f3mez Rivas","year":"2024","unstructured":"G\u00f3mez Rivas J, Ortega Polledo LE, De La Parra S\u00e1nchez I, Guti\u00e9rrez Hidalgo B, Mart\u00edn Monterrubio J, Marug\u00e1n \u00c1lvarez MJ, et al. Current status of neoadjuvant treatment before surgery in high-risk localized prostate cancer. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/CANCERS17010099.","journal-title":"Cancers (Basel)"},{"key":"4350_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/J.EURURO.2022.09.009","volume":"83","author":"G Devos","year":"2023","unstructured":"Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, et al. ARNEO: a randomized phase II trial of neoadjuvant Degarelix with or without Apalutamide prior to radical prostatectomy for high-risk prostate cancer. Eur Urol. 2023;83:508\u201318. https:\/\/doi.org\/10.1016\/J.EURURO.2022.09.009.","journal-title":"Eur Urol"},{"key":"4350_CR35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/S41391-022-00496-8","volume":"25","author":"LS Lee","year":"2022","unstructured":"Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:741\u20138. https:\/\/doi.org\/10.1038\/S41391-022-00496-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"4350_CR36","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1200\/JCO.2022.40.16_SUPPL.5085","volume":"40","author":"DA Bastos","year":"2022","unstructured":"Bastos DA, Coelho R, Cardili L, Galiza F, Ilario EN, Viana P, et al. Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: pathologic response and PSMA imaging correlates. J Clin Oncol. 2022;40:5085\u20135085. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_SUPPL.5085.","journal-title":"J Clin Oncol"},{"key":"4350_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clgc.2022.10.009","volume":"21","author":"EN Ilario","year":"2023","unstructured":"Ilario EN, Bastos DA, Guglielmetti GB, Murta CB, Cardili L, Cordeiro MD, et al. Perioperative morbidity of radical prostatectomy after intensive neoadjuvant androgen blockade in men with high-risk prostate cancer: results of phase II trial compared to a control group. Clin Genitourin Cancer. 2023;21:43\u201354. https:\/\/doi.org\/10.1016\/j.clgc.2022.10.009.","journal-title":"Clin Genitourin Cancer"},{"key":"4350_CR38","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of Enzalutamide and Leuprolide with or without Abiraterone. J Clin Oncol. 2019;37:923\u201331. https:\/\/doi.org\/10.1200\/JCO.18.01777.","journal-title":"J Clin Oncol"},{"key":"4350_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer. J Urol. 2021;206:80\u20137. https:\/\/doi.org\/10.1097\/JU.0000000000001702.","journal-title":"J Urol"},{"key":"4350_CR40","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/CNCR.35170","volume":"130","author":"RR McKay","year":"2024","unstructured":"McKay RR, Xie W, Yang X, Acosta A, Rathkopf D, Laudone VP, et al. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: results of part 2 of a randomized phase 2 trial. Cancer. 2024;130:1629\u201341. https:\/\/doi.org\/10.1002\/CNCR.35170.","journal-title":"Cancer"},{"key":"4350_CR41","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2020.38.15_SUPPL.5504","volume":"38","author":"E Efstathiou","year":"2020","unstructured":"Efstathiou E, Boukovala MA, Spetsieris N, Wen S, Hoang A, Weldon JA, et al. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). J Clin Oncol. 2020;38:5504\u20135504. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_SUPPL.5504.","journal-title":"J Clin Oncol"},{"key":"4350_CR42","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/JU.0000000000004163","volume":"212","author":"N Shore","year":"2024","unstructured":"Shore N, Hafron J, Saltzstein D, Brown G, Belkoff L, Aggarwal P, et al. Apalutamide for high-risk localized prostate cancer following radical prostatectomy (Apa-RP). J Urol. 2024;212:682\u201391. https:\/\/doi.org\/10.1097\/JU.0000000000004163.","journal-title":"J Urol"},{"key":"4350_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/JAMA.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433\u20139. https:\/\/doi.org\/10.1001\/JAMA.294.4.433.","journal-title":"JAMA"},{"key":"4350_CR44","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1002\/CNCR.10977","volume":"95","author":"PA Kupelian","year":"2002","unstructured":"Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer. 2002;95:2302\u20137. https:\/\/doi.org\/10.1002\/CNCR.10977.","journal-title":"Cancer"},{"key":"4350_CR45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/J.EURURO.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75:967\u201387. https:\/\/doi.org\/10.1016\/J.EURURO.2018.10.011.","journal-title":"Eur Urol"},{"key":"4350_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/J.1464-410X.2011.10422.X","volume":"109","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32\u20139. https:\/\/doi.org\/10.1111\/J.1464-410X.2011.10422.X.","journal-title":"BJU Int"},{"key":"4350_CR47","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2024.42.16_SUPPL.5101","volume":"42","author":"EM Posadas","year":"2024","unstructured":"Posadas EM, Gay HA, Rodgers JP, Morgan TM, Xiao Y, Yu J, et al. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: initial results from RTOG 3506 (STEEL). J Clin Oncol. 2024;42:5101\u20135101. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_SUPPL.5101.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4350_CR48","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","volume":"41","author":"PT Tran","year":"2023","unstructured":"Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol. 2023;41(6):1307\u201317. https:\/\/doi.org\/10.1200\/JCO.22.01662.","journal-title":"J Clin Oncol"},{"key":"4350_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/J.EURURO.2025.12.001","author":"PL Nguyen","year":"2026","unstructured":"Nguyen PL, Kollmeier MA, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, et al. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. Eur Urol Eur Urol. 2026. https:\/\/doi.org\/10.1016\/J.EURURO.2025.12.001.","journal-title":"Eur Urol Eur Urol"},{"key":"4350_CR50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/J.IJROBP.2025.08.028","volume":"123","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Karrison TG, Sandler HM, Posadas E, Chen RC, Wallace RE, et al. A double-blinded placebo-controlled biomarker stratified randomized trial of apalutamide (APA) and radiotherapy for recurrent prostate cancer (NRG GU006, BALANCE trial). Int J Radiat Oncol, Biol, Phys. 2025;123:1197\u20138. https:\/\/doi.org\/10.1016\/J.IJROBP.2025.08.028.","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"4350_CR51","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMOA2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365. https:\/\/doi.org\/10.1056\/NEJMOA2303974.","journal-title":"N Engl J Med"},{"key":"4350_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2510310","author":"ND Shore","year":"2025","unstructured":"Shore ND, Luz MD, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMOA2510310.","journal-title":"N Engl J Med"},{"key":"4350_CR53","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.23.01157","volume":"42","author":"R Aggarwal","year":"2024","unstructured":"Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, et al. PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol. 2024;42:1114. https:\/\/doi.org\/10.1200\/JCO.23.01157. (Lippincott Williams and Wilkins).","journal-title":"J Clin Oncol"},{"key":"4350_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/J.EURURO.2025.08.020","volume":"89","author":"G Marvaso","year":"2026","unstructured":"Marvaso G, Francolini G, Achard V, Gomez-Iturriaga A, Slevin F, Zilli T, et al. Should we embark on \u201cEMBARK\u201d? Reassessing the role of radiotherapy and androgen receptor pathway inhibitors in the era of next-generation imaging. Eur Urol. 2026;89:5\u20137. https:\/\/doi.org\/10.1016\/J.EURURO.2025.08.020.","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04350-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:39:52Z","timestamp":1790159992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04350-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4350"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04350-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Felipe Cou\u00f1ago has received sponsored research from J&J and Recordati; has participated in advisory boards or consulting activities for J&J and AstraZeneca; has received honoraria for lectures and educational activities from J&J, Roche Farma, AstraZeneca, Astellas, Recordati, Ipsen, Accord and Bayer; and has received travel support from AstraZeneca, Astellas, J&J, Roche Farma, Recordati and Bayer. Fernando L\u00f3pez-Campos has received sponsored research from J&J, Astellas and Bayer; has participated in advisory boards or consulting activities for J&J, Astellas, Bayer, Recordati and Ipsen; has received honoraria for lectures and educational activities from J&J, Astellas, Bayer, Recordati, Ipsen and Accord; and has received travel support from Astellas, J&J, Recordati and Bayer. The remaining authors declare that they have no conflicts of interest associated with this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based exclusively on previously published data and does not include any new studies involving human participants or animals conducted by the authors. Therefore, ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study informed consent is not required.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}